{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:02:06Z","timestamp":1789016526019,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":445,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA171983"],"award-info":[{"award-number":["P01CA171983"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1194\/jlr.m091876","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T19:55:17Z","timestamp":1554753317000},"page":"1078-1086","update-policy":"https:\/\/doi.org\/10.1194\/jlr.f110.005975","source":"Crossref","is-referenced-by-count":47,"title":["Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-\u03baB-dependent P-glycoprotein upregulation"],"prefix":"10.1016","volume":"60","author":[{"given":"Su-Fern","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Dunton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy A.F.","family":"Morad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhimant","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Conaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantu","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles C.","family":"Cabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Feith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas P.","family":"Loughran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.M091876_bib1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","article-title":"Drug rechallenge and treatment beyond progression-implications for drug resistance","volume":"10","author":"Kuczynski","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1194\/jlr.M091876_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-pharmtox-010715-103111","article-title":"Toward a better understanding of the complexity of cancer drug resistance","volume":"56","author":"Gottesman","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1194\/jlr.M091876_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.drup.2012.02.001","article-title":"Drug resistance: still a daunting challenge to the successful treatment of AML","volume":"15","author":"Shaffer","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"10.1194\/jlr.M091876_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1194\/jlr.M091876_bib5","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood."},{"key":"10.1194\/jlr.M091876_bib6","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.95.12.7024","article-title":"The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis","volume":"95","author":"Smyth","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.M091876_bib7","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1074\/jbc.272.3.1682","article-title":"Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells","volume":"272","author":"Lavie","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M091876_bib8","doi-asserted-by":"crossref","first-page":"36075","DOI":"10.1074\/jbc.C100345200","article-title":"The multidrug resistance P-glycoprotein. Oligomeric state and intramolecular interactions","volume":"276","author":"Taylor","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M091876_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenet. Genomics."},{"key":"10.1194\/jlr.M091876_bib10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/81.2.116","article-title":"Expression of a multidrug resistance gene in human cancers","volume":"81","author":"Goldstein","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1194\/jlr.M091876_bib11","first-page":"111","article-title":"MDR1 gene expression in acute myeloid leukemia: clinical correlation","volume":"94","author":"Lin","year":"1995","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1194\/jlr.M091876_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-007-0269-7","article-title":"CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age","volume":"86","author":"van den Heuvel-Eibrink","year":"2007","journal-title":"Ann. Hematol."},{"key":"10.1194\/jlr.M091876_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0145-2126(95)00134-4","article-title":"Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML)","volume":"20","author":"Samdani","year":"1996","journal-title":"Leuk. Res."},{"key":"10.1194\/jlr.M091876_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/83.10.708","article-title":"MDR1 gene expression and treatment outcome in acute myeloid leukemia","volume":"83","author":"Pirker","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1194\/jlr.M091876_bib15","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2003-07-2490","article-title":"Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies","volume":"104","author":"Mahadevan","year":"2004","journal-title":"Blood."},{"key":"10.1194\/jlr.M091876_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat. Rev. Cancer."},{"key":"10.1194\/jlr.M091876_bib17","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.bbamem.2006.10.018","article-title":"A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death","volume":"1758","author":"Taha","year":"2006","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.M091876_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4419-6741-1_13","article-title":"Cancer treatment strategies targeting sphingolipid metabolism","volume":"688","author":"Oskouian","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1194\/jlr.M091876_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1194\/jlr.M091876_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/ctm.ctm_7_17","article-title":"SKI-178: a multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models","volume":"3","author":"Hengst","year":"2017","journal-title":"Cancer Transl. Med."},{"key":"10.1194\/jlr.M091876_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2016-06-720433","article-title":"Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia","volume":"129","author":"Powell","year":"2017","journal-title":"Blood."},{"key":"10.1194\/jlr.M091876_bib22","doi-asserted-by":"crossref","first-page":"83208","DOI":"10.18632\/oncotarget.13079","article-title":"Acid ceramidase is upregulated in AML and represents a novel therapeutic target","volume":"7","author":"Tan","year":"2016","journal-title":"Oncotarget."},{"key":"10.1194\/jlr.M091876_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41420-018-0075-0","article-title":"Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies","volume":"4","author":"Lewis","year":"2018","journal-title":"Cell Death Discov."},{"key":"10.1194\/jlr.M091876_bib24","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2741\/2843","article-title":"Acid ceramidase inhibition: a novel target for cancer therapy","volume":"13","author":"Liu","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1194\/jlr.M091876_bib25","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1074\/jbc.M115.666909","article-title":"Acid ceramidase in melanoma: expression, localization, and effects of pharmacological inhibition","volume":"291","author":"Realini","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M091876_bib26","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1517\/14728220903357512","article-title":"Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy","volume":"13","author":"Liu","year":"2009","journal-title":"Expert Opin. Ther. Targets."},{"key":"10.1194\/jlr.M091876_bib27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/138945008785132358","article-title":"Molecular targeting of acid ceramidase: implications to cancer therapy","volume":"9","author":"Zeidan","year":"2008","journal-title":"Curr. Drug Targets."},{"key":"10.1194\/jlr.M091876_bib28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood-2007-11-121871","article-title":"Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes","volume":"112","author":"Shah","year":"2008","journal-title":"Blood."},{"key":"10.1194\/jlr.M091876_bib29","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.4161\/cbt.6.9.4623","article-title":"The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy","volume":"6","author":"Saad","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1194\/jlr.M091876_bib30","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-04-2329","article-title":"Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs","volume":"65","author":"Gouaz\u00e9","year":"2005","journal-title":"Cancer Res."},{"key":"10.1194\/jlr.M091876_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1476-4598-9-145","article-title":"Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling","volume":"9","author":"Liu","year":"2010","journal-title":"Mol. Cancer."},{"key":"10.1194\/jlr.M091876_bib32","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/0006-2952(89)90134-2","article-title":"Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression","volume":"38","author":"McGrath","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"10.1194\/jlr.M091876_bib33","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4161\/cbt.29186","article-title":"Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression","volume":"15","author":"Doi","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1194\/jlr.M091876_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1388-1981(03)00122-7","article-title":"Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death","volume":"1633","author":"Dagan","year":"2003","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.M091876_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00280-007-0465-0","article-title":"Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells","volume":"61","author":"Holman","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1194\/jlr.M091876_bib36","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1194\/jlr.D800051-JLR200","article-title":"Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers","volume":"50","author":"Shaner","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M091876_bib37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1021\/bi991943f","article-title":"Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60\/VCR human acute myeloid leukemia cell line","volume":"39","author":"Ogretmen","year":"2000","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.M091876_bib38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.1998.16.3.872","volume":"16","author":"L\u00f6wenberg","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1194\/jlr.M091876_bib39","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1182\/blood-2001-12-0354","article-title":"Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study","volume":"100","author":"Anderson","year":"2002","journal-title":"Blood."},{"key":"10.1194\/jlr.M091876_bib40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1158\/1535-7163.633.3.5","article-title":"Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy","volume":"3","author":"Gouaz\u00e9","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1194\/jlr.M091876_bib41","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/nature09128","article-title":"Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2","volume":"465","author":"Alvarez","year":"2010","journal-title":"Nature."},{"key":"10.1194\/jlr.M091876_bib42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/bbrc.1997.6598","article-title":"Sphingosine-1-phosphate mobilizes intracellular calcium and activates transcription factor NF-kappa B in U937 cells","volume":"234","author":"Shatrov","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1194\/jlr.M091876_bib43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/sj.onc.1206056","article-title":"NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells","volume":"22","author":"Bentires-Alj","year":"2003","journal-title":"Oncogene."},{"key":"10.1194\/jlr.M091876_bib44","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet."},{"key":"10.1194\/jlr.M091876_bib45","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/ijc.21666","article-title":"Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia","volume":"118","author":"Kim","year":"2006","journal-title":"Int. J. Cancer."},{"key":"10.1194\/jlr.M091876_bib46","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood."},{"key":"10.1194\/jlr.M091876_bib47","unstructured":"FDA approves venetoclax in combination for AML in adults. Accessed April 14, 2019, at https:\/\/www.fda.gov\/Drugs\/Information\u00adOnDrugs\/ApprovedDrugs\/ucm626499.htm."},{"key":"10.1194\/jlr.M091876_bib48","unstructured":"FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia. Accessed April 14, 2019, at https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm614128.htm."},{"key":"10.1194\/jlr.M091876_bib49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","article-title":"Emerging therapeutic drugs for AML","volume":"127","author":"Stein","year":"2016","journal-title":"Blood."},{"key":"10.1194\/jlr.M091876_bib50","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"key":"10.1194\/jlr.M091876_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood."},{"key":"10.1194\/jlr.M091876_bib52","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature."},{"key":"10.1194\/jlr.M091876_bib53","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","article-title":"Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999","volume":"116","author":"Cripe","year":"2010","journal-title":"Blood."},{"key":"10.1194\/jlr.M091876_bib54","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.onc.1205117","article-title":"Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling","volume":"21","author":"Kuo","year":"2002","journal-title":"Oncogene."},{"key":"10.1194\/jlr.M091876_bib55","doi-asserted-by":"crossref","first-page":"7411","DOI":"10.1038\/s41598-017-07606-w","article-title":"Complete Acid Ceramidase ablation prevents cancer-initiating cell formation in melanoma cells","volume":"7","author":"Lai","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1194\/jlr.M091876_bib56","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1042\/BJ20050047","article-title":"The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids","volume":"389","author":"Eckford","year":"2005","journal-title":"Biochem. J."},{"key":"10.1194\/jlr.M091876_bib57","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4161\/cbt.11.2.14624","article-title":"Dysregulation of sphingolipid metabolism in cancer","volume":"11","author":"Ryland","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1194\/jlr.M091876_bib58","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.yexcr.2011.03.004","article-title":"P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells","volume":"317","author":"Chapman","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1194\/jlr.M091876_bib59","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jnci\/93.5.347","article-title":"Targeting ceramide metabolism\u2013a strategy for overcoming drug resistance","volume":"93","author":"Senchenkov","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1194\/jlr.M091876_bib60","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.bbamem.2008.03.007","article-title":"How lipid flippases can modulate membrane structure","volume":"1778","author":"Devaux","year":"2008","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.M091876_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.plipres.2016.08.003","article-title":"Lipid somersaults: Uncovering the mechanisms of protein-mediated lipid flipping","volume":"64","author":"Pomorski","year":"2016","journal-title":"Prog. Lipid Res."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520322483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520322483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.M091876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T14:16:15Z","timestamp":1663251375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227520322483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0022227520322483"],"URL":"https:\/\/doi.org\/10.1194\/jlr.m091876","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}